Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort
Mohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, Nurulamin M Noor, Anushka Herath, Achini Withanachchi, Robin Dart, Sreedhar Subramanian, Miles Parkes, Mark A Samaan, Tim Raine, Peter M Irving · 2026
Read Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort by Mohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, Nurulamin M Noor, Anushka Herath, Achini Withanachchi, Robin Dart, Sreedhar Subramanian, Miles Parkes, Mark A Samaan, Tim Raine, Peter M Irving (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13353223.txt.
Description
Mohmmed Tauseef Sharip leads a 2026 real-world cohort study of mirikizumab in ulcerative colitis, split by prior ustekinumab use. Trial data excluded patients who had taken ustekinumab, leaving a practical gap. Records from three United Kingdom tertiary centres covered 100 adults with at least 12 weeks of follow-up, including 36 with prior ustekinumab exposure.
Treatment persistence at 3 months was 72 percent, with no clear gap between groups. Symptom scores fell from 5.8 at baseline down to 3.3 at the 3-month review visit. Faecal calprotectin dropped from 1094 to 586 micrograms per gram over the same span. Scope scores improved from a mean of 4.4 before induction down to 2.7 after induction had ended. Prior ustekinumab did not blunt response in adjusted models.
Catalog record
| CREATOR | Mohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, Nurulamin M Noor, Anushka Herath, Achini Withanachchi, Robin Dart, Sreedhar Subramanian, Miles Parkes, Mark A Samaan, Tim Raine, Peter M Irving |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28583 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |